Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Description and nomenclature of Neisseria meningitidis capsule locus.

Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, Bentley SD, Maiden MC.

Emerg Infect Dis. 2013 Apr;19(4):566-73. doi: 10.3201/eid1904.111799.

2.

Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Moran EE, Burden R, Labrie JE 3rd, Wen Z, Wang XM, Zollinger WD, Zhang L, Pinto VB.

Clin Vaccine Immunol. 2012 May;19(5):659-65. doi: 10.1128/CVI.00070-12. Epub 2012 Mar 29. Erratum in: Clin Vaccine Immunol. 2012 Oct;19(10)1705.

3.

Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.

Zollinger WD, Babcock JG, Moran EE, Brandt BL, Matyas GR, Wassef NM, Alving CR.

Vaccine. 2012 Jan 17;30(4):712-21. doi: 10.1016/j.vaccine.2011.11.084. Epub 2011 Dec 3.

PMID:
22138211
4.

An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.

Pinto VB, Moran EE, Cruz F, Wang XM, Fridman A, Zollinger WD, Przysiecki CT, Burden R.

Vaccine. 2011 Oct 13;29(44):7752-8. doi: 10.1016/j.vaccine.2011.07.124. Epub 2011 Aug 7.

PMID:
21827811
5.

Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Schmiel DH, Moran EE, Keiser PB, Brandt BL, Zollinger WD.

Infect Immun. 2011 Oct;79(10):4146-56. doi: 10.1128/IAI.05125-11. Epub 2011 Jul 18.

6.

Meningococcal serogroup B vaccines: will they live up to expectations?

Zollinger WD, Poolman JT, Maiden MC.

Expert Rev Vaccines. 2011 May;10(5):559-61. doi: 10.1586/erv.11.41. No abstract available.

7.

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD.

Vaccine. 2011 Feb 4;29(7):1413-20. doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1.

PMID:
21199704
8.

A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.

Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE 3rd, Schmiel DH, Pinto V, Chen P, Zollinger WD.

Vaccine. 2010 Oct 8;28(43):6970-6. doi: 10.1016/j.vaccine.2010.08.048. Epub 2010 Aug 21.

PMID:
20732470
9.

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine.

Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie JE 3rd, Moran EE, Brandt BL, Ionin B, Marques R, Wu M, Chen P, Stoddard MB, Keiser PB.

Vaccine. 2010 Jul 12;28(31):5057-67.

PMID:
20653107
10.

Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Zollinger WD, Moran EE, Schmiel DH.

Clin Vaccine Immunol. 2009 Dec;16(12):1789-95. doi: 10.1128/CVI.00255-09. Epub 2009 Oct 14.

11.

Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis.

Keiser PB, Miller LB, Biggs-Cicatelli S, Zollinger WD.

Vaccine. 2009 Nov 16;27(49):6809-13. doi: 10.1016/j.vaccine.2009.09.019. Epub 2009 Sep 15.

PMID:
19761833
12.

Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada.

Tsang RS, Law DK, Tyler SD, Stephens GS, Bigham M, Zollinger WD.

Can J Infect Dis Med Microbiol. 2005 May;16(3):171-4.

14.

Fulminant supraglottitis from Neisseria meningitidis.

Kortepeter MG, Adams BL, Zollinger WD, Gasser RA Jr.

Emerg Infect Dis. 2007 Mar;13(3):502-4. No abstract available.

15.

Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada.

Tsang RS, Henderson AM, Cameron ML, Tyler SD, Tyson S, Law DK, Stoltz J, Zollinger WD.

J Clin Microbiol. 2007 Jun;45(6):1753-8. Epub 2007 Apr 18.

16.
17.

Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Law DK, Lorange M, Ringuette L, Dion R, Giguère M, Henderson AM, Stoltz J, Zollinger WD, De Wals P, Tsang RS.

J Clin Microbiol. 2006 Aug;44(8):2743-9.

18.
21.
22.

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD.

Infect Immun. 2002 Feb;70(2):702-7.

23.

Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers.

Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD.

Vaccine. 1999 Aug 20;18(1-2):160-72.

PMID:
10501246
24.

Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.

Wedege E, Caugant DA, Musacchio A, Saunders NB, Zollinger WD.

Clin Diagn Lab Immunol. 1999 Jul;6(4):639-42.

25.

Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Saunders NB, Shoemaker DR, Brandt BL, Moran EE, Larsen T, Zollinger WD.

Infect Immun. 1999 Jan;67(1):113-9.

26.

Immunological and molecular characterization of three variant subtype P1.14 strains of Neisseria meningitidis.

Saunders NB, Brandt BL, Warren RL, Hansen BD, Zollinger WD.

Infect Immun. 1998 Jul;66(7):3218-22.

27.

Confirmation of suspicious cases of meningococcal meningitis by PCR and enzyme-linked immunosorbent assay.

Saunders NB, Shoemaker DR, Brandt BL, Zollinger WD.

J Clin Microbiol. 1997 Dec;35(12):3215-9.

28.

A randomized, placebo-controlled study of oral cimetidine as an immunopotentiator of parenteral immunization with a group B meningococcal vaccine.

Drabick JJ, Tang DB, Moran EE, Trofa AF, Foster JS, Zollinger WD.

Vaccine. 1997 Jul;15(10):1144-8.

PMID:
9269060
30.

Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Devi SJ, Zollinger WD, Snoy PJ, Tai JY, Costantini P, Norelli F, Rappuoli R, Frasch CE.

Infect Immun. 1997 Mar;65(3):1045-52.

31.

Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.

Van De Verg LL, Hartman AB, Bhattacharjee AK, Tall BD, Yuan L, Sasala K, Hadfield TL, Zollinger WD, Hoover DL, Warren RL.

Infect Immun. 1996 Dec;64(12):5263-8.

32.

Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease.

Hammerschmidt S, Müller A, Sillmann H, Mühlenhoff M, Borrow R, Fox A, van Putten J, Zollinger WD, Gerardy-Schahn R, Frosch M.

Mol Microbiol. 1996 Jun;20(6):1211-20.

PMID:
8809773
33.

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS.

J Infect Dis. 1996 May;173(5):1157-63.

PMID:
8627067
35.

The use of filter paper monoclonal antibodies in a Dot-blot test for typing Neisseria meningitidis B.

De-Gaspari EN, Ribeiro-Filho AA, Zollinger WD.

Braz J Med Biol Res. 1994 Dec;27(12):2889-93.

PMID:
7550010
36.

Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies.

Scholten RJ, Kuipers B, Valkenburg HA, Dankert J, Zollinger WD, Poolman JT.

J Med Microbiol. 1994 Oct;41(4):236-43.

PMID:
7523677
38.

GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3.

Livingston PO, Calves MJ, Helling F, Zollinger WD, Blake MS, Lowell GH.

Vaccine. 1993 Sep;11(12):1199-204.

PMID:
8256501
39.

Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease.

Zollinger WD, Boslego J, Moran E, Garcia J, Cruz C, Ruiz S, Brandt B, Martinez M, Arthur J, Underwood P, et al.

NIPH Ann. 1991 Dec;14(2):211-2; discussion 213. No abstract available.

PMID:
1812433
40.

Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977-1989.

Ashton FE, Mancino L, Ryan AJ, Poolman JT, Abdillahi H, Zollinger WD.

Can J Microbiol. 1991 Aug;37(8):613-7.

PMID:
1954574
42.

Meningococcal vaccines--present and future.

Zollinger WD, Moran E.

Trans R Soc Trop Med Hyg. 1991;85 Suppl 1:37-43. Review.

PMID:
1803695
43.

Preparation of proteosome-based vaccines. Correlation of immunogenicity with physical characteristics.

Ruegg CL, Jaffe RI, Köster B, Sadoff JC, Zollinger WD, Lowell GH, Strand M.

J Immunol Methods. 1990 Dec 31;135(1-2):101-9.

PMID:
2125617
44.

Antibodies to meningococcal H.8 (Lip) antigen fail to show bactericidal activity.

Bhattacharjee AK, Moran EE, Zollinger WD.

Can J Microbiol. 1990 Feb;36(2):117-22.

PMID:
2110857
45.
46.

Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.

Lowell GH, Ballou WR, Smith LF, Zollinger WD, Hockmeyer WT.

Trans R Soc Trop Med Hyg. 1989;83 Suppl:101-2.

PMID:
2696152
47.

Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.

Rosenqvist E, Harthug S, Frøholm LO, Høiby EA, Bøvre K, Zollinger WD.

J Clin Microbiol. 1988 Aug;26(8):1543-8.

48.

Common epitopes of pilin of Neisseria meningitidis.

Stephens DS, Whitney AM, Schoolnik GK, Zollinger WD.

J Infect Dis. 1988 Aug;158(2):332-42.

PMID:
2457056
49.

Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.

Lowell GH, Ballou WR, Smith LF, Wirtz RA, Zollinger WD, Hockmeyer WT.

Science. 1988 May 6;240(4853):800-2.

PMID:
2452484
50.

Purification and characterization of H.8 antigen from group B Neisseria meningitidis.

Bhattacharjee AK, Moran EE, Ray JS, Zollinger WD.

Infect Immun. 1988 Apr;56(4):773-8.

Supplemental Content

Loading ...
Support Center